WO2000070025A1 - Methods of using rnase p reaction mechanisms of action - Google Patents
Methods of using rnase p reaction mechanisms of action Download PDFInfo
- Publication number
- WO2000070025A1 WO2000070025A1 PCT/US2000/013946 US0013946W WO0070025A1 WO 2000070025 A1 WO2000070025 A1 WO 2000070025A1 US 0013946 W US0013946 W US 0013946W WO 0070025 A1 WO0070025 A1 WO 0070025A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- trna
- binding
- rnasep
- holoenzyme
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 96
- 238000006243 chemical reaction Methods 0.000 title description 19
- 230000009471 action Effects 0.000 title description 7
- 230000007246 mechanism Effects 0.000 title 1
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 269
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 252
- 229920001184 polypeptide Polymers 0.000 claims description 244
- 230000027455 binding Effects 0.000 claims description 119
- 238000003776 cleavage reaction Methods 0.000 claims description 96
- 230000007017 scission Effects 0.000 claims description 95
- 108010025076 Holoenzymes Proteins 0.000 claims description 79
- 230000000694 effects Effects 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 31
- 241000894006 Bacteria Species 0.000 claims description 30
- 239000005557 antagonist Substances 0.000 claims description 29
- 239000000556 agonist Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 8
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 8
- 241000191940 Staphylococcus Species 0.000 claims 6
- 241000194017 Streptococcus Species 0.000 claims 6
- 108090000621 Ribonuclease P Proteins 0.000 abstract description 62
- 102000004167 Ribonuclease P Human genes 0.000 abstract description 61
- 150000001875 compounds Chemical class 0.000 abstract description 30
- 230000001580 bacterial effect Effects 0.000 abstract description 18
- 102000004389 Ribonucleoproteins Human genes 0.000 abstract description 6
- 108010081734 Ribonucleoproteins Proteins 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 230000000845 anti-microbial effect Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 198
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 177
- 102000004169 proteins and genes Human genes 0.000 description 143
- 102000040430 polynucleotide Human genes 0.000 description 141
- 108091033319 polynucleotide Proteins 0.000 description 141
- 239000002157 polynucleotide Substances 0.000 description 140
- 235000018102 proteins Nutrition 0.000 description 140
- 108020004414 DNA Proteins 0.000 description 91
- 210000004027 cell Anatomy 0.000 description 88
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 86
- 101710089766 Ribonuclease P protein component Proteins 0.000 description 70
- 239000012634 fragment Substances 0.000 description 68
- 239000000758 substrate Substances 0.000 description 68
- 239000002773 nucleotide Substances 0.000 description 57
- 125000003729 nucleotide group Chemical group 0.000 description 57
- 230000003993 interaction Effects 0.000 description 54
- 239000013598 vector Substances 0.000 description 53
- 239000001103 potassium chloride Substances 0.000 description 43
- 235000011164 potassium chloride Nutrition 0.000 description 43
- 239000013612 plasmid Substances 0.000 description 42
- 230000014509 gene expression Effects 0.000 description 38
- 241000588724 Escherichia coli Species 0.000 description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 35
- 239000000047 product Substances 0.000 description 34
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 32
- 239000000126 substance Substances 0.000 description 31
- 108091026890 Coding region Proteins 0.000 description 29
- 239000000523 sample Substances 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 25
- 239000000872 buffer Substances 0.000 description 24
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- 108020001507 fusion proteins Proteins 0.000 description 23
- 102000037865 fusion proteins Human genes 0.000 description 23
- 239000003446 ligand Substances 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 21
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 238000013518 transcription Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 239000004202 carbamide Substances 0.000 description 16
- 238000010367 cloning Methods 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 238000012163 sequencing technique Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 229920001223 polyethylene glycol Polymers 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000012216 screening Methods 0.000 description 14
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 230000002209 hydrophobic effect Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 13
- 238000004364 calculation method Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000002255 enzymatic effect Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 102000006382 Ribonucleases Human genes 0.000 description 11
- 108010083644 Ribonucleases Proteins 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 229910001629 magnesium chloride Inorganic materials 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 108091092562 ribozyme Proteins 0.000 description 10
- 238000004448 titration Methods 0.000 description 10
- 235000014469 Bacillus subtilis Nutrition 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 206010000269 abscess Diseases 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 235000004252 protein component Nutrition 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 108091029865 Exogenous DNA Proteins 0.000 description 7
- 108010074860 Factor Xa Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 101150076304 spp gene Proteins 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 206010048038 Wound infection Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010031252 Osteomyelitis Diseases 0.000 description 5
- 230000004570 RNA-binding Effects 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 5
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000287 crude extract Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 201000007119 infective endocarditis Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- 208000004020 Brain Abscess Diseases 0.000 description 4
- 206010007882 Cellulitis Diseases 0.000 description 4
- 206010007918 Cellulitis orbital Diseases 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 108010069514 Cyclic Peptides Proteins 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010014568 Empyema Diseases 0.000 description 4
- 238000001535 HNCA Methods 0.000 description 4
- 206010021531 Impetigo Diseases 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 208000000493 Orbital Cellulitis Diseases 0.000 description 4
- 206010033078 Otitis media Diseases 0.000 description 4
- 206010057182 Periorbital cellulitis Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 241000295644 Staphylococcaceae Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 206010044248 Toxic shock syndrome Diseases 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 208000013086 acute epiglottitis Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000009881 electrostatic interaction Effects 0.000 description 4
- 206010014665 endocarditis Diseases 0.000 description 4
- 206010014801 endophthalmitis Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 208000001606 epiglottitis Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229920000140 heteropolymer Polymers 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 201000003453 lung abscess Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010043778 thyroiditis Diseases 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 208000031729 Bacteremia Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000012565 NMR experiment Methods 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 102100034574 P protein Human genes 0.000 description 3
- 108010015724 Prephenate Dehydratase Proteins 0.000 description 3
- 108010001267 Protein Subunits Proteins 0.000 description 3
- 102000002067 Protein Subunits Human genes 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- 206010044302 Tracheitis Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 3
- -1 cationic lipid Chemical class 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000010399 physical interaction Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 238000001472 pulsed field gradient Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001551 total correlation spectroscopy Methods 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- UEUPTUCWIHOIMK-UHFFFAOYSA-N 2'-deoxy-AMP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(OP(O)(O)=O)C(CO)O1 UEUPTUCWIHOIMK-UHFFFAOYSA-N 0.000 description 2
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 2
- KAUQJMHLAFIZDU-UHFFFAOYSA-N 6-Hydroxy-2-naphthoic acid Chemical compound C1=C(O)C=CC2=CC(C(=O)O)=CC=C21 KAUQJMHLAFIZDU-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- 239000004475 Arginine Chemical group 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 235000003325 Ilex Nutrition 0.000 description 2
- 241000209035 Ilex Species 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 208000029212 bacterial myositis Diseases 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- KHWCHTKSEGGWEX-UHFFFAOYSA-N deoxyadenylic acid Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(O)=O)O1 KHWCHTKSEGGWEX-UHFFFAOYSA-N 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000005421 electrostatic potential Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 101150106875 malE gene Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Chemical group 0.000 description 2
- 239000002184 metal Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108090000446 ribonuclease T(2) Proteins 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010066798 Bacterial tracheitis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100439299 Caenorhabditis elegans cgt-3 gene Proteins 0.000 description 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
- 101100257262 Caenorhabditis elegans soc-1 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100456896 Drosophila melanogaster metl gene Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 241000210651 Enterobacteria phage 1 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017916 Gastroenteritis staphylococcal Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 238000002130 HNCOCA Methods 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000204025 Mycoplasma capricolum Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010038975 Retroperitoneal abscess Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- 101150050559 SOAT1 gene Proteins 0.000 description 1
- 101150116552 SPI gene Proteins 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 208000008582 Staphylococcal Food Poisoning Diseases 0.000 description 1
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 102220537846 Teashirt homolog 1_C39S_mutation Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010044250 Toxic shock syndrome staphylococcal Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000013378 biophysical characterization Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000000239 endoribonucleolytic effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- BDWFYHUDXIDTIU-UHFFFAOYSA-N ethanol;propane-1,2,3-triol Chemical compound CCO.OCC(O)CO BDWFYHUDXIDTIU-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010076560 isospaglumic acid Proteins 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- LFEUVBZXUFMACD-UHFFFAOYSA-H lead(2+);trioxido(oxo)-$l^{5}-arsane Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-][As]([O-])([O-])=O.[O-][As]([O-])([O-])=O LFEUVBZXUFMACD-UHFFFAOYSA-H 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000010995 multi-dimensional NMR spectroscopy Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
- 238000012585 nuclear overhauser effect spectroscopy experiment Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 101150051303 rnpA gene Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 201000005789 splenic abscess Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000017756 staphylococcal toxic-shock syndrome Diseases 0.000 description 1
- 201000002190 staphyloenterotoxemia Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 238000012932 thermodynamic analysis Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 101150097091 tnpA gene Proteins 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012582 total correlation spectroscopy experiment Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000004337 transverse relaxation-optimized spectroscopy Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26006—Ribonuclease IV (3.1.26.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- This invention relates to newly identified polynucleotides, polypeptides encoded by certain of these polynucleotides, molecular complexes of RNAs and polypeptides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides.
- the invention relates particularly to such polynucleotides and polypeptides from Staphylococci, especially S. aureus.
- This invention also relates to inhibiting the biosynthesis, assembly or action of such polynucleotides and/or polypeptides and to the use of such inhibitors in therapy.
- This invention relates to a novel bacterial ribonucleoprotein complex and the component parts thereof. More specifically, this invention relates to RNase P, particularly RNase P from Staphylococcus aureus, and the use of RNase P or components thereof in screens for the identification of antimicrobial compounds and to the use of such compounds in therapy.
- Staphylococci make up a medically important genera of microbes. They are known to produce two types of disease, invasive and toxigenic. Invasive infections are characterized generally by abscess formation effecting both skin surfaces and deep tissues. S. aureus is the second leading cause of bacteremia in cancer patients. Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacterial endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of Staphylococci. The manifestation of these diseases result from the actions of exotoxins as opposed to tissue invasion and bacteremia. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome.
- Staphylococcus aureus infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate Staphylococcus aureus strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.
- Staphylococcal proteins associated with pathogenicity e.g., coagulase, hemolysins, leucocidins and exo- and enterotoxins
- additional targets are always useful because it is appreciated that the target of a antimicrobial screen can often bias the outcome.
- new targets allow for the discovery of new classes of antimicrobials.
- This invention provides a novel ribonucleoprotein complex, particularly such complex from Staphylococcus aureus, and the separately isolated RNA and protein components thereof.
- polynucleotides which encode the protein and RNA components of such a complex.
- the invention provides polynucleotides having the DNA sequences given herein.
- the invention also relates to novel oligonucleotides derived from the sequences given herein which can act, for example, as antisense inhibitors of the expression of the RNA or protein components.
- the oligonucleotides or fragments or derivatives thereof can also be used to directly inhibit catalytic activity or indirectly inhibit activity by interference with RNA protein complex formation.
- the protein and the RNA components are also useful as targets in screens designed to identify antimicrobial compounds. It is an object of the invention to provide polypeptides that have been identified as novel RNaseP RNA or holoenzymes by homology between the amino acid sequence set out in Table 1 [SEQ ID NO: 2] and a known amino acid sequence or sequences of other proteins, such as B. subtilis RNase P protein.
- the polynucleotide comprises a region encoding RNaseP polypeptides comprising the sequence set out in Table 1 [SEQ ID NO:l] which includes a full length gene, or a variant thereof.
- a novel RNaseP protein from Staphylococcus aureus comprising the amino acid sequence of Table 1 [SEQ ID NO:2], or a variant thereof.
- an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Staphylococcus aureus WCUH 29 strain contained in the deposited strain
- a further aspect of the invention there are provided isolated nucleic acid molecules encoding RNaseP, particularly Staphylococcus aureus RNaseP, including mRNAs, cDNAs, genomic DNAs and catalytic RNAs Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful va ⁇ ants thereof, and compositions comprising the same
- a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization
- particularly preferred embodiments of the invention are naturally occurring alle c variants of RNaseP and polypeptides encoded thereby
- RNaseP Staphylococcus aureus
- inhibitors to such polypeptides useful as antibacterial agents, including, for example, antibodies
- products, compositions and methods for assessing RNaseP expression treating disease, for example, disease, such as, infections of the upper respiratory tract (e g , otitis media, bacte ⁇ al tracheitis, acute epiglottitis, thyroiditis).
- disease such as, infections of the upper respiratory tract (e g , otitis media, bacte ⁇ al tracheitis, acute epiglottitis, thyroiditis).
- lower respiratory e g , empyema, lung abscess
- cardiac e g , infective endocarditis
- gastrointestinal e g , secretory diarrhoea, splenic abscess, retrope ⁇ toneal abscess
- CNS e g , cerebral abscess
- eye e g , blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis
- kidney and u ⁇ nary tract e g , epididymitis, intrarenal and pe ⁇ neph ⁇ c absces, toxic shock syndrome
- skin e g , impetigo, fol culitis, cutaneous abscesses, cellulitis, wound infection, bacte ⁇ al myositis
- bone and joint e g , septic arth ⁇ tis, osteomyelitis
- methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comprising: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal in response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.
- RNaseP agonists and antagonists preferably bacteriostatic or bacteriocidal agonists and antagonists.
- compositions comprising a
- RNaseP polynucleotide or a RNaseP polypeptide for administration to a cell or to a multicellular organism.
- Figure 2 illustrates NMR-Spectroscopy and sequential assignment of RNaseP protein from S auieus
- Figure 3 illustrates survey of parameters for the structure calculation of RNaseP protein, plotted against the sequence
- the solid line refers to the polypeptide backbone atoms (N, C ⁇ , C), the dashed line to all non-hydrogen atoms
- Figure 4 illustrates solution structure of S aureus RNaseP protein
- Figure 5 illustrates multiple sequence alignment of RNaseP protein from 11 different procaryotic species Numbering and location of regular secondary structures
- Figure 6 illustrates 'H-chemical shift differences of the backbone amide protons as a consequence of ligand binding
- a Binding of mononucleotides or mononucleosides to RNaseP protein GMP (diamond), AMP (triangle down), 2'-deoxy-AMP (triangle up), equimolar mixture of CMP and UMP (square), equimolar mixture of the cytidinenucleoside and u ⁇ dinenucleoside (circle) Titrations were performed under the following conditions final ligand concentration, 40 mM, protein concentration, 800 ⁇ M, 100 mM sodium chloride
- b Titration of RNaseP protein with the following homo-ohgonucleotides at two different salt concentrations AI Q (filled triangle down), (2'-deoxy-A)jo (filled triangle up Sample conditions for the first two experiments were ligand concentration 420 ⁇ M, protein concentration, 640mM, 300 mM sodium chloride), The following two
- Figure 7 illustrates substrate binding surface of RNaseP protein as defined by NMR spectroscopy CP-plot of the RNaseP protein structure, superimposed with the electrostatic potential surface of the residues in the interaction site as characterized by chemical shift changes m Fig 6b Purple cylinders indicate the position of the ⁇ -hehces Approximate locations of the 4 major interaction regions (cmp Figure 6b) are indicated by the letters A- D The orientation of the molecule by approx 30 degrees clockwise around the vertical axis versus the orientation in Fig 4c to show the partial involvement of helix 3 in ligand interactions Glossary:
- “Host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.
- Identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
- identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
- Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., 1. Molec. Biol.
- BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., 1. Mol. Biol. 215: 403-410 (1990).
- a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1.
- a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
- These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
- a polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2.
- up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
- These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
- isolated means altered “by the hand of man” from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both.
- a polynucleotide or a polypeptide naturally present in a living organism is not
- isolated but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
- Polynucleotide(s) generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- Polynucleotide(s) include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double- stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double- stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the strands in such regions may be from the same molecule or from different molecules.
- the regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules.
- polynucleot ⁇ de(s) also includes DNAs or RNAs as desc ⁇ bed above that contain one or more modified bases
- DNAs or RNAs with backbones modified for stability or for other reasons are “polynucleot ⁇ de(s)” as that term is intended herein
- DNAs or RNAs comp ⁇ sing unusual bases, such as inosine, or modified bases, such as t ⁇ tylated bases, to name just two examples are polynucleotides as the term is used herein
- polynucleot ⁇ de(s) as it is employed herein embraces such chemically, enzymatically or metabohcally modified forms of polynucleotides, as well as
- Polypept ⁇ de(s) refers to any peptide or protein comp ⁇ sing two or more amino acids joined to each other by peptide bonds or modified peptide bonds
- Polypept ⁇ de(s) refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins
- Polypeptides may contain amino acids other than the 20 gene encoded amino acids
- Polypept ⁇ de(s)” include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques Such modifications are well desc ⁇ bed in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art It will be appreciated that the same type of modification may be present in the same or varying degree at several sites m a given polypeptide Also, a given polypeptide may contain many types of modifications Modifications can occur anywhere in a polypeptide, including the peptide backbone
- Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.
- Variant(s) is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties.
- a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
- a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
- a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
- a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.
- RNase P The ribonucleoprotein, RNase P, plays a key role in the biosynthesis of transfer RNA (tRNA), itself a key intermediate in protein biosynthesis.
- RNase P functions to process precursor RNAs into mature tRNAs by endoribonucleolytic action.
- the complex in prokaryotes is composed of two subunits: a catalytic RNA and protein co-factor.
- the invention relates to novel RNaseP polypeptides and polynucleotides as described in greater detail below.
- the invention relates to polypeptides and polynucleotides of a novel RNaseP of Staphylococcus aureus, which is related by amino acid sequence homology to RNase P polypeptide set forth in SEQ ID NO:2.
- the invention relates especially to RNaseP having the nucleotide and amino acid sequences set out in Table 1, SEQ ID NO: 1 and SEQ ID NO: 2 respectively, and to the RNaseP nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby.
- the invention also relates to the RNase P RNA component, particularly in its catalytic for, and sequences from which such component is transcribed.
- RNase P RNA Component is
- a novel RNase P protein component from S. aureus has been identified and is characterized by the amino acid sequence given in [SEQ ID NO:2] in which the S. aureus (Sau) sequence is aligned with sequences from other microorganisms.
- the full length sequence encoding the intact RNase P protein component can be obtained by probing a genomic library by for example in situ colony hybridization (infra) using a probe(s) generated based on the sequences given in [SEQ ID NOS:l and 2]. TABLE 1 RNaseP Polynucleotide and Polypeptide Sequences
- polypeptides of the invention include the polypeptide of Table 1 [SEQ ID NO:2] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of RNaseP, and also those which have at least 70% identity to the polypeptide of Table 1 [SEQ ID NO:2] or the relevant portion, preferably at least 80% identity to the polypeptide of Table 1 [SEQ ID NO:2], and more preferably at least 90% similarity (more preferably at least 90% identity) to the polypeptide of Table 1 [SEQ ID NO:2] and still more preferably at least 95% similarity (still more preferably at least 95% identity) to the polypeptide of Table 1 [SEQ ID NO:2] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.
- the invention also includes polypeptides of the formula set forth in Table 1 (D) [SEQ ID NO:2] wherein, at the amino terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R ] and R2 is any amino acid residue, and n is an integer between 1 and 1000. Any stretch of amino acid residues denoted by either R group, where R is greater than 1 , may be either a heteropolymer or a homopolymer, preferably a heteropolymer.
- a fragment is a variant polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides.
- fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.
- Preferred fragments include, for example, truncation polypeptides having a portion of the amino acid sequence of Table 1 [SEQ ID NO:2], or of variants thereof, such as a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus.
- Degradation forms of the polypeptides of the invention in a host cell are also preferred.
- fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta- sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
- biologically active fragments which are those fragments that mediate activities of RNaseP, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or immunogenic in an animal, especially in a human. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of Staphylococcus aureus or the ability to initiate, or maintain cause disease in an individual, particularly a human.
- Variants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention.
- Polynucleotides of the invention :
- Another aspect of the invention relates to isolated polynucleotides, including the full length gene, that encode the RNaseP polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NO:2] and polynucleotides closely related thereto and variants thereof.
- a polynucleotide of the invention encoding RNaseP polypeptide or RNA may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using Staphylococcus aureus WCUH 29 cells as starting material, followed by obtaining a full length clone.
- a library of clones of chromosomal DNA of Staphylococcus aureus WCUH 29 in E.coli or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence
- a radiolabeled oligonucleotide preferably a 17-mer or longer
- Clones carrying DNA identical to that of the probe can then be distinguished using stringent conditions
- sequencing primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence
- such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone Suitable techniques are desc ⁇ bed by Mamatis, T , F ⁇ tsch, E F and Sambrook et al , MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed , Cold Sp ⁇ ng Har
- SEQ ID NO 1 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in Table 1 [SEQ ID NO 2] with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known in the art
- the polynucleotide of SEQ ID NO 1 between nucleotide number 1 through number 351 encodes the polypeptide of SEQ ID NO 2
- the stop codon begins at nucleotide number 352 of SEQ ID NO 1
- RNaseP of the invention is structurally related to other proteins of the RNase P family, as shown by the results of sequencing the DNA encoding RNaseP of the deposited strain
- the protein exhibits greatest homology to B subtihs protein among known proteins
- RNaseP of Table 1 [SEQ ID NO 2] has significant identity and simila ⁇ ty over its entire length with the ammo acid sequence of B subtihs RNase P polypeptide
- the invention provides a polynucleotide sequence identical over its entire length to the coding sequence in Table 1 [SEQ ID NO 1 ] Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence
- the polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transc ⁇ bed, non- translated sequences, termination signals, ⁇ bosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional ammo acids
- a marker sequence that facilitates pu ⁇ fication of the fused polypeptide can be encoded
- the marker sequence is a hexa-histidine peptide
- Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.
- a preferred embodiment of the invention is a polynucleotide of comprising nucleotide 1 to 351 or 354 set forth in SEQ ID NO: l of Table 1 which encode the RNaseP polypeptide.
- the invention also includes polynucleotides of the formula set forth in Table 1 (C)[SEQ ID NO: l and (F)[SEQ ID NO:3] wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, Rj and R2 is any nucleic acid residue, and n is an integer between 1 and 3000. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1 , may be either a heteropolymer or a homopolymer, preferably a heteropolymer.
- a preferred embodiment for the sequence set forth in Table 1 (F) [SEQ ID NO:3] has Ri or R 2 being between 1 and 10 or 1 and 20, and especially being 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
- the invention also provides RNA transcribed from such polynucleotides, particularly catalytic RNAs.
- polynucleotide encoding a polypeptide encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the Staphylococcus aureus RNaseP having the amino acid sequence set out in Table 1 [SEQ ID NO:2].
- the term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain coding and/or non-coding sequences.
- the invention further relates to variants of the polynucleotides described herein that encode for variants of the polypeptide having the deduced amino acid sequence of Table 1 [SEQ ID NO:2].
- Variants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.
- N is also used.
- N means that any of the four DNA or RNA bases may appear at such a designated position in the DNA or RNA sequence, except that, in preferred embodiments, N can not be a base that when taken in combination with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon in such reading frame.
- RNaseP variants that have the amino acid sequence of RNaseP polypeptide of Table 1 [SEQ ID NO:2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of RNaseP.
- polynucleotides that are at least 50%, 60% or 70% identical over their entire length to a polynucleotide encoding RNaseP polypeptide having an amino acid sequence set out in Table 1 [SEQ ID NO:2], and polynucleotides that are complementary to such polynucleotides.
- polynucleotides that comprise a region that is at least 80% identical over its entire length to a polynucleotide encoding RNaseP polypeptide of the deposited strain and polynucleotides complementary thereto.
- polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.
- Preferred embodiments of the invention are polynucleotides that are at least 50%,
- polynucleotides that comprise a region that is at least 80% identical over its entire length to an RNaseP polynucleotide of the deposited strain and polynucleotides complementary thereto.
- polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred.
- those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred. It is especially preferred that these polynucleotides be RNAs, especially catalytic RNAs.
- Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ID NO: 1 ] or as the RNase P RNA component transcribed by the DNA of SEQ ID NO:3, 4 or 14.
- the invention further relates to polynucleotides that hybridize to the herein above- described sequences.
- the invention especially relates to polynucleotides that hybridize under stringent conditions to the herein above-described polynucleotides.
- stringent conditions and “stringent hybridization conditions” mean hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.
- An example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support in O. lx SSC at about 65°C.
- Hybridization and wash conditions are well known and exemplified in Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., ( 1989), particularly Chapter 11 therein.
- the invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO:3 or SEQ ID NO:4 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:l or SEQ ID NO:3 or SEQ ID NO:4 respectively or a fragment thereof; and isolating said DNA sequence.
- Fragments useful for obtaining such a polynucleotide include, for example, probes and primers described elsewhere herein.
- polynucleotide assays of the invention may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding RNaseP and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the RNaseP gene.
- Such probes generally will comprise at least 15 bases.
- such probes will have at least 30 bases and may have at least 50 bases.
- Particularly preferred probes will have at least 30 bases and will have 50 bases or less.
- Polynucleotides of the invention that are oligonucleotides derived from the sequences of SEQ ID NOS: l and/or 2 and/or 3 and/or 4 and/or 14 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained
- the invention also provides polynucleotides that may encode a poK peptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance)
- Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things
- the additional amino acids may be processed away from the mature protein by cellular enzymes
- a precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be removed before activation Generally, such precursors are called proproteins.
- a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed dunng processing steps that produce active and mature forms of the polypeptide.
- a partial homolog to B. subtilis RNase P RNA was identified in a proprietary S. aureus database comprising sequences from randomly sequenced S. auie s DNA library in an E. coli host.
- a PCR primer based on these data was designed to the 3' end of the gene (primer
- the structural gene has been cloned behind a T7 promoter, sequenced and shown to be highly related to B. subtihs homolog.
- the precise S. aureus genomic sequence encoding (transcribing) helices PI and P2 may be determined by skilled artisans using methods and compounds of the invention, such as the degenerate primer described above [SEQ ID NO: 13].
- the exact 5' end has been determined by primer extension analysis using endogenous S. aureus RNA isolated from S. aureus WCUH29.
- the sequence of the first 20 nucleotides of RNaseP RNA 5' end as determined by this primer extension analysis is: 5 ' -GUUCUGAUAUUUUGGGUAAU-3 ' [SEQ ID NO: 14]. Further Description and Definitions:
- the coding region of the RNaseP gene may be isolated, for example, by screening using a deposit containing a Staphylococcus aureus WCUH 29 strain which has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein "NCIMB"), 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland on 1 1 September 1995 and assigned NCIMB Deposit No. 40771. It was referred to as Staphylococcus aureus WCUH29 on deposit.
- the Staphylococcus aureus strain deposit is referred to herein as "the deposited strain” or as "the DNA of the deposited strain.”
- the deposited strain contains the full length RNaseP gene.
- the sequence of the polynucleotides contained in the deposited strain, as well as the amino acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.
- the deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure.
- the strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent.
- the deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. ⁇ 1 12.
- a license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.
- nucleotide sequences disclosed herein can also be obtained by synthetic chemical techniques known in the art or can be obtained from S. aureus WCUH 29 by probing a DNA preparation with probes constructed from the particular sequences disclosed herein.
- oligonucleotides derived from a disclosed sequence can act as PCR primers in a process of PCR-based cloning of the sequence from a bacterial genomic source. It is recognized that such sequences will also have utility in diagnosis of the type of infection the pathogen has attained.
- a polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA.
- the DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand.
- the coding sequence which encodes the polypeptide may be identical to the coding sequence shown or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encoding the same polypeptide.
- polynucleotide encoding a polypeptide encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
- the present invention therefore includes polynucleotides, wherein the coding sequence for the mature polypeptide may be fused in the same reading frame to a polynucleotide sequence which aids in expression and secretion of a polypeptide from a host cell, for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell.
- the polypeptide having a leader sequence is a preprotein and may have the leader sequence cleaved by the host cell to form the mature form of the polypeptide.
- the polynucleotides may also encode for a proprotein which is the mature protein plus additional 5' amino acid residues.
- a mature protein having a prosequence is a proprotein and is an inactive form of the protein. Once the prosequence is cleaved an active mature protein remains.
- the polynucleotide of the present invention may encode for a mature protein, or for a protein having a prosequence or for a protein having both a prosequence and a presequence (leader sequence).
- leader sequence the amino acid sequences provided herein show a methionine residue at the NH2-terminus. It is appreciated, however, that during post-translational modification of the peptide, this residue may be deleted. Accordingly, this invention contemplates the use of both the methionine- containing and the methionineless amino terminal variants of each protein disclosed herein.
- the polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence at either the 5' or 3' terminus of the gene which allows for purification of the polypeptide of the present invention.
- the marker sequence may be a hexa-histidine tag supplied by the pQE series of vectors (supplied commercially by Quiagen Inc.) to provide for purification of the polypeptide fused to the marker in the case of a bacterial host.
- the maltose binding protein (MBP) fusion system may be employed.
- the gene of interest is fused the malE gene encoding the MBP (supplied by New England BioLabs)
- the fusion product is purified in a one step procedure based on the MBP affinity for maltose
- a pre-engineered Xa cleavage site allows for efficient removal of the MBP component from the gene product of interest
- Plasmids' are designated b> a lower case p preceded and/or followed by capital letters and/or numbers
- the starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from a ⁇ ailable plasmids in accord with published procedures
- equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan
- “Digestion” of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA
- the various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan
- typically 1 ⁇ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 ⁇ l of buffer solution
- typically 5 to 50 ⁇ g of DNA are digested with 20 to 250 units of enzyme in a larger volume
- Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer
- Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions
- After digestion the reaction is electrophoresed directly on an agarose gel to isolate the desired fragment Size separation of the cleaved fragments is generally performed using a 1 % percent agarose gel
- Oligonucleotides refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized Such synthetic oligonucleotides have no 5' phosphate and thus will not hgate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kmase A synthetic oligonucleotide will hgate to a fragment that has not been dephosphorylated
- Ligand refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T , et al , supra , p 146) Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA hgase ("hgase") per 0 5 ⁇ g of approximately equimolar amounts of the DNA fragments to be hgated
- hgase DNA hgase
- the polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.
- a “replicon” is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.
- a "vector” is a replicon, such as a plasmid, phage, or cosmid, to which another
- DNA segment may be attached so as to bring about the replication of the attached segment.
- double-stranded DNA molecule refers to the polymeric form of deoxyribonucleotides (bases adenine, guanine, thymine, or cytosine) in a double-stranded helix, both relaxed and supercoiled. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.
- linear DNA molecules e.g., restriction fragments
- sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA).
- a DNA "coding sequence of” or a “nucleotide sequence encoding" a particular protein is a DNA sequence which is transcribed and translated into a polypeptide when placed under the control of appropriate regulatory sequences.
- a “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence.
- the promoter sequence is bound at the 3' terminus by a translation start codon (e.g., ATG) of a coding sequence and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
- a transcription initiation site (conveniently defined by mapping with nuclease SI), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
- Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT” boxes.
- Prokaryotic promoters contain the -10 and -35 consensus sequences.
- control sequences refers collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the expression (i.e., the transcription and translation) of a coding sequence in a host cell.
- a control sequence "directs the expression" of a coding sequence in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.
- a "host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous DNA sequence.
- a cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane.
- Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
- the exogenous DNA may be maintained on an episomal element, such as a plasmid.
- a stably transformed or transfected cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cell containing the exogenous DNA.
- a “clone” is a population of cells derived from a single cell or common ancestor by mitosis.
- a “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.
- a "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature.
- the present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
- polypeptide of the invention by recombinant techniques by expressing a polynucleotide encoding said polypeptide in a host and recovering the expressed product.
- polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector.
- the vector may be, for example, in the form of a plasmid, a cosmid, a phage, etc.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes.
- the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- Suitable expression vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA.
- any other vector may be used as long as it is replicable and viable in the host.
- host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention.
- Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al., BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.
- bacterial cells such as streptococci, staphylococci, enterococci E. coli, streptomyces and Bacillus subtilis cells
- fungal cells such as yeast cells and Aspergillus cells
- insect cells such as Drosophila S2 and Spodoptera Sf9 cells
- animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells
- plant cells include bacterial cells, such as streptococci, staphylococci, enterococci E. coli, streptomyces and Bacillus subtilis cells
- fungal cells such as yeast cells and Aspergillus cells
- insect cells such as Drosophila S2 and Spodoptera Sf9 cells
- animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells
- plant cells include bacterial cells, such as streptococci, staphylococci, enteroco
- vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
- vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses
- the expression system constructs may contain control regions that regulate as well as engender expression.
- any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard.
- the appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al, MOLECULAR CLONING, A LABORATORY MANUAL, (supra).
- the appropriate DNA sequence may be inserted into the vector by a variety of procedures.
- the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art.
- the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
- promoter for example, LTR or SV40 promoter, the E. coli. lac or trp, the phage lambda PL promoter and other promoters known to control expression of genes in eukaryotic or prokaryotic cells or their viruses.
- the expression vector may also contains a ribosome binding site for translation initiation and/or a transcription terminator.
- the vector may also include appropriate sequences for amplifying expression.
- the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
- the gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control" elements), so that the DNA sequence encoding the desired protein is transcribed into RNA in the host cell transformed by a vector containing this expression construction.
- the coding sequence may or may not contain a signal peptide or leader sequence.
- the polypeptides of the present invention can be expressed using, for example, the E. coli tac promoter or the protein A gene (spa) promoter and signal sequence. Leader sequences can be removed by the bacterial host in post-translational processing. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437; 4,338,397.
- Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- Two appropriate vectors are PKK232-8 and PCM7.
- Particular named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda PR, PL and trp.
- Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
- regulatory sequences which allow for regulation of the expression of the protein sequences relative to the growth of the host cell.
- Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
- Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.
- An expression vector is constructed so that the particular coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the "control" of the control sequences (i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence).
- control i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence.
- Modification of the coding sequences may be desirable to achieve this end. For example, in some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.
- control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above.
- a vector such as the cloning vectors described above.
- the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site.
- recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly- expressed gene to direct transcription of a downstream structural sequence.
- the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.
- the vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.
- the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above.
- the constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation.
- the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence.
- a promoter operably linked to the sequence.
- Bacterial pET-3 vectors (Stratagene), pQE70, pQE60, pQE-9 (Qiagen), pbs, pDIO, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNHl ⁇ a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).
- Eukaryotic pBlueBacIII (Invitrogen), pWLNEO, pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).
- any other plasmid or vector may be used as long as they are replicable and viable in the host.
- Examples of recombinant DNA vectors for cloning and host cells which they can transform include the bacteriophage 1 (E. coli), pBR322 (E. coli), pACYC177 (E. coli), pKT230 (gram-negative bacteria), pGV1 106 (gram-negative bacteria), pLAFRl (gram- negative bacteria), pME290 (non-£. coli gram-negative bacteria), pHV14 (E.
- sequences which cause the secretion of the polypeptide from the host organism may be desirable to add sequences which cause the secretion of the polypeptide from the host organism, with subsequent cleavage of the secretory signal.
- Polypeptides can be expressed in host cells under the control of appropriate promoters.
- Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
- Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby inco ⁇ orated by reference.
- the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
- appropriate means e.g., temperature shift or chemical induction
- Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
- Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.
- the polypeptide of the present invention may be produced by growing host cells transformed by an expression vector described above under conditions whereby the polypeptide of interest is expressed. The polypeptide is then isolated from the host cells and purified. If the expression system secretes the polypeptide into growth media, the polypeptide can be purified directly from the media. If the polypeptide is not secreted, it is isolated from cell lysates or recovered from the cell membrane fraction.
- polypeptide is localized to the cell surface, whole cells or isolated membranes can be used as an assayable source of the desired gene product.
- Polypeptide expressed in bacterial hosts such as E. coli may require isolation from inclusion bodies and refolding.
- the mature protein has a very hydrophobic region which leads to an insoluble product of overexpression, it may be desirable to express a truncated protein in which the hydrophobic region has been deleted. The selection of the appropriate growth conditions and recovery methods are within the skill of the art.
- the polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
- HPLC high performance liquid chromatography
- polypeptides of the present invention may be glycosylated or may be non-glycosylated.
- Polypeptides of the invention may also include an initial methionine amino acid residue.
- RNA polymerase as according to standard conditions - usually as recommended by the supplier, e.g., Promega.
- the plasmid is linearized with an appropriate restriction enzyme generating a linear dsDNA comprising the full length gene encoding the RNase PRNA.
- the RNA is purified either from a preparative denaturing acrylamide gel or is precipitated prior to use in in vitro cleavage assays.
- the substrates for the RNase P RNA and the RNA complexed with its protein RNase P protein
- RNase P protein can be obtained by in vitro transcription of cloned genes.
- the RNA can also be prepared by automated synthesis
- This invention provides a method of screening drugs to identify those which interfere with the RNA portion, the protein portion and/ or the intact RNA/protein complex of the RNase P described herein, which method comprises measuring the interference of the activity of the protein and/or RNA by a test drug For example since the RNA portion selected has a catalytic activity, after suitable purification and formulation the activity of the RNA can be followed by its ability to convert its natural or synthetic RNA substrates By inco ⁇ orating different chemically synthesized test compounds or natural products into such an assay of enzymatic activity one is able to detect those additives which compete with the natural or synthetic substrate or otherwise inhibit enzymatic activity
- Polypeptides of the invention may also be used to assess the binding of small molecule substrates and hgands in, for example, cells, cell-free preparations, chemical hbra ⁇ es, and natural product mixtures
- substrates and hgands may be natural substrates and hgands or may be structural or functional mimetics See, e g , Co gan et al , Current Protocols in Immunology 1(2) Chapter 5 ( 1991 )
- the invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of RNaseP polypeptides or polynucleotides, particularly those compounds that are bacte ⁇ ostatic and/or bacte ⁇ ocidal
- the method of screening may involve high-throughput techniques
- a synthetic reaction mix a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof
- comp ⁇ sing RNaseP polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a RNaseP agonist or antagonist
- the ability of the candidate molecule to agonize or antagonize the RNaseP polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate Molecules that bind gratuitously, i e , without inducing the effects of RNaseP polypeptide are most likely to
- Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing RNaseP-induced activities, thereby preventing the action of RNaseP by excluding RNaseP from binding.
- Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented.
- small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules.
- Other potential antagonists include antisense molecules (see Okano, 1. Neurochem. 56: 560 (1991); OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL (1988), for a description of these molecules).
- Preferred potential antagonists include compounds related to and variants of RNaseP.
- Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds.
- the encoded protein upon expression, can be used as a target for the screening of antibacterial drugs.
- the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.
- the invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection.
- the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive bacteria, to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block RNaseP protein-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases (Rosenshine et al , Infect Irninun 60 221 1 ( 1992), to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial RNaseP proteins that mediate tissue damage and, to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques
- the antagonists and agonists of the invention may be employed, for instance, to inhibit and
- Biotin is introduced in to an appropriate position within the RNA substrate and the 5' terminus labeled with 3 p.
- the substrate is linked via streptavidin within a 96-well plate Following RNase P dependent hydrolysis of the substrate, the radiolabelled 5' leader cleavage product is released into the bulk solution phase, and subject to scintillation counting
- the RNA substrate is bound to a streptavidin-coated flashplate such that the release of the radioactive 6-mer into the solution phase results in a decrease in signal
- cyclic peptide libraries were constructed with flanking cysteine residues to allow efficient disulfide bond formation and cyclization during phage assembly.
- the streptavidin bound crystal structures of two disulfide bridged cyclic peptides showed both peptides to be in beta-turn conformations (Kahn, M. (Guest, Ed., 1993) Tetrahedron 49, Symp. 50, 3433-3677).
- Beta-turns are key recognition elements in many biological interactions therefore effort has been focused on the design of small constrained beta-turn mimics (Kahn, M. (Guest Ed., 1993) Tetrahedron 49, Symp. 50, 3433-3677). This approach, when applied to RNase P, could identify cyclic peptides suitable for peptide mimic synthesis as inhibitor molecules.
- a cyclic octapeptide phage display library may be constructed and used to identify peptides that interact with defined RNA domains.
- RNA recognition motifs for RNase P RNA Ml RNA
- the technology is based on the repeated selection and amplification of RNA fragments that specifically bind to a protein with high affinities (Szostak, J.W., TIBS 17: 89-93 (1992)). Fragment libraries based on the S. aureus and E.
- RNase P RNAs may be constructed for the in ⁇ ttro synthesis of RNA fragments and the subsequent selection of molecules that bind their respective proteins
- Chemical and enzymatic structure probing technologies may be employed in combination with protein/RNA protection studies to map the interactive sites SELEX based on the resulting RNA fragment(s) may be further exploited to determine the minimal structural requirements for RNA recognition Disruption of RNase P Assembly
- RNA RNA/Drug Interactions The identification of a protein/RNA-fragment pair permits the development of a screen for compounds that disrupt their assembly Drug induced disruption of labeled RNA bound to immobilized protein (biotin/streptavidin) would result in the concomitant decrease/loss of the signal generated by the presence of the RNA RNA/Drug Interactions
- RNase P RNA fragments that confer drug resistance may be sequenced and expressed in vitro for chemical and enzymatic structure probing in the presence and absence of the drug in an attempt to map the binding site SELEX may be applied to lead compounds in an attempt to identify the minimal structural requirements for drug binding RNase P Substrates
- RNA substrates may be chemically synthesized for HTP screening including both pre-tRNA and pre-4 5S RNA derivatives RNA-Hgand interactions involving ⁇ bose 2'-hydroxyl groups of specific nucleotides may be probed via chemical synthesis of the approp ⁇ ately modified RNA fragment
- 2'-methoxy and 2'-fluoro ⁇ bonucleot ⁇ des analogues can be used, the latter being preferred on steric grounds
- Nucleotides lacking a 2'-subst ⁇ tuent adopt the undesired A -endo configuration The invention also relates to inhibitors identified by any of the techniques described herein Because of the enzymatic nature of RNase P action, it is appreciated that inhibitors may be identified which act as transition state mimics, inhibitors of product release or inhibitors of substrate binding Diagnostic Assays This invention is also related to the use of the RNaseP polynucleotides of the
- Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique p ⁇ or to analysis RNA or cDNA may also be used in the same ways Using amplification, characte ⁇ zation of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene Deletions and insertions can be detected by a change in size of the amplified product in compa ⁇ son to the genotype of a reference sequence Point mutations can be identified by hybridizing amplified DNA to labeled RNaseP polynucleotide sequences Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denatur
- a diagnostic assay in accordance with the invention for detecting over- expression of RNaseP protein compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techniques that can be used to determine levels of a RNaseP protein, in a sample de ⁇ ved from a host are well-known to those of skill in the art Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays Antibodies
- Antibodies as used herein includes monoclonal and polyclonal antibodies, chime ⁇ c, single chain, simiamzed antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunolglobulin expression library
- the Fab fragment may also be prepared from its parent monoclonal antibody by enzyme treatment, for example using papain to cleave the Fab portion from the Fc portion
- Antibodies generated against the polypeptides of the invention can be obtained by admimstenng the polypeptides or epitope-bea ⁇ ng fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols The antibody so obtained will then bind the polypeptides itself In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide
- any technique known in the art that provides antibodies produced by continuous cell line cultures can be used Examples include vanous techniques, such as those in Kohler, G and Milstein, C , Nature 256 495-497 (1975), Kozbor et al , Immunology Today 4 72 (1983), Cole et al , pg 77-
- the hyb ⁇ domas are screened to select a cell line with high binding affinity and favorable cross reaction with other staphylococcal species using one or more of the original polypeptide and/or the fusion protein
- the selected cell line is cultured to obtain the desired Mab
- phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v- genes of lymphocytes from humans screened for possessing anti-RNaseP or from naive libraries (McCafferty, J et al , (1990), Nature 348, 552-554, Marks, J et al , (1992) Biotechnology 10, 779-783)
- the affinity of these antibodies can also be improved by chain shuffling (Clackson, T et al , (1991) Nature 352, 624-628)
- the antibody should be screened again for high affinity to the polypeptide and/or fusion protein As mentioned above, a fragment of the final antibody may be prepared
- the antibody may be either intact antibody of M r approx 150,000 or a derivative of it, for example a Fab fragment or a Fv fragment as described in Skerra, A and Pluckthun, A., Science 240 1038-1040 (1988) If two antigen binding domains are present each domain may be directed against a different epitope - termed hispecific' antibodies If two antigen binding domains are present each domain may be directed against a different epitope - termed hispecific' antibodies
- polypeptides in which one or more of the amino acid residues are modified may be used.
- Such peptides may, for example, be prepared by substitution, addition, or rearrangement of amino acids or by chemical modification thereof. All such substitutions and modifications are generally well known to those skilled in the art of peptide chemistry.
- the above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides to purify the polypeptides by affinity chromatography.
- antibodies against RNaseP- polypeptide may be employed to treat infections, particularly bacterial infections and especially disease, such as, infections of the upper respiratory tract (e.g., otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retroperitoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and perinephric absces, toxic shock syndrome), skin (e.g., impetigo, folli
- the antibody is prepared by expression of a DNA polymer encoding said antibody in an appropriate expression system such as described above for the expression of polypeptides of the invention.
- the choice of vector for the expression system will be determined in part by the host, which may be a prokaryotic cell, such as __. coli (preferably strain B) or Streptomyces sp. or a eukaryotic cell, such as a mouse C127, mouse myeloma, human HeLa, Chinese hamster ovary, filamentous or unicellular fungi or insect cell.
- the host may also be a transgenic animal or a transgenic plant (for example, as described in Hiatt, A. et al, Nature 340:76-78(1989).
- Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses, derived from, for example, baculoviruses and vaccinia.
- Polypeptide variants include antigenically, epitopically or immunologically equivalent variants that form a particular aspect of this invention.
- the term "antigenically equivalent derivative” as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host.
- the term “immunologically equivalent derivative” as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.
- the polypeptide such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken.
- the fusion protein may provide stability to the polypeptide.
- the antigen may be associated, for example by conjugation, with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH).
- BSA bovine serum albumin
- KLH keyhole limpet haemocyanin
- a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.
- the antibody or variant thereof is modified to make it less immunogenic in the individual.
- the antibody may most preferably be "humanized"; where the complimentarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody , for example as described in Jones, P. et al. (1986), Nature 321 , 522-525 or Tempest et al., (1991) Biotechnology 9, 266-273.
- the modification need not be restricted to one of "humanization”; other primate sequences (for example Newman, R. et al, Biotechnology 10: 1455-1460 (1992)) may also be used.
- a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al., Hum Mol Genet 1992, 1 :363, Mantho ⁇ e et al., Hum. Gene Ther. 1963:4, 419), delivery of DNA complexed with specific protein carriers (Wu et al., 1 Biol Chem. 1989: 264,16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, PNAS USA, 1986:83,9551).
- a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al., Hum Mol Genet 1992, 1 :363, Mantho ⁇ e et al., Hum. Gene Ther. 1963:4, 419), delivery of DNA complexed with specific protein carriers (Wu et al., 1 Biol Chem. 1989: 264,16985), coprecipitation
- Vaccines encapsulation of DNA in various forms of liposomes (Kaneda et al., Science 1989:243,375), particle bombardment (Tang et al., Nature 1992, 356:152, Eisenbraun et al., DNA Cell Biol 1993, 12:791) and in vivo infection using cloned retroviral vectors (Seeger et al., PNAS USA 1984:81 ,5849).
- Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the individual with RNaseP, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly Staphylococcus aureus infection. Also provided are methods whereby such immunological response slows bacterial replication.
- Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of RNaseP, or a fragment or a variant thereof, for expressing RNaseP, or a fragment or a variant thereof in vivo in order to induce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine- producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not
- an immunological response such as, to produce antibody and/ or T cell immune response, including, for example, cytokine- producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not
- One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise
- Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid
- a further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a RNaseP or protein coded therefrom, wherein the composition comprises a recombinant RNaseP or protein coded therefrom comp ⁇ sing DNA which codes for and expresses an antigen of said RNaseP or protein coded therefrom
- the immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells
- a RNaseP polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties
- fused recombinant protein preferably further comprises an antigenic co-protein, such as hpoprotein D from Hemophilus influenzae, Glutathione-S-transferase (GST) or beta- galactosidase, relatively large co-proteins which solubihze the protein and facilitate production and purification thereof
- the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system
- the co-protem may be attached to either the amino or carboxy terminus of the first protein
- compositions particularly vaccine compositions, and methods comp ⁇ sing the polypeptides or polynucleotides of the invention and im unostimulatory DNA sequences, such as those described in Sato, Y et al Science 273 352 (1996)
- polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immunization experiments in animal models of infection with Staphylococcus aureus will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacte ⁇ al infection, particularly Staphylococcus aureus infection, in mammals, particularly humans
- the polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue
- tissue damage include wounds in skin or connective tissue caused, e g , by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina
- the invention also includes a vaccine formulation which comprises an immunogenic recombinant protein of the invention together with a suitable carrier Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal
- Formulations suitable for parenteral administration include aqueous and non- aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacte ⁇ ostats and solutes which render the formulation insotonic with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-d ⁇ ed condition requiring only the addition of the sterile liquid carrier immediately p ⁇ or to use
- the vaccine formulation may also include adjuvant systems for enhancing the immunogenicity
- the invention also relates to compositions comp ⁇ sing the polynucleotide or the polypeptides discussed above or their agonists or antagonists
- the polypeptides of the invention may be employed in combination with a non-ste ⁇ le or sterile earner or carriers for use with cells, tissues or organisms such as a pharmaceutical earner suitable for administration to a subject
- Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable earner or excipient
- Such earners may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol ethanol and combinations thereof
- the formulation should suit the mode of administration
- the invention further relates to diagnostic and pharmaceutical packs and kits comp ⁇ sing one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention
- compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intrapentoneal, intramuscular, subcutaneous, tranasal or intradermal routes among others
- the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably lsoto c
- the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams
- Such topical formulations may also contain compatible conventional earners, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions
- Such earners may constitute from about 1 % to about 98% by weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation
- the daily dosage level of the active agent will be from 0 01 mg/kg to 10 mg/kg, typically around 1 mg/kg
- the physician am event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual
- the above dosages are exemplary of the
- In-dwelling devices include surgical implants, prosthetic devices and catheters, 1 e , devices that are introduced to the body of an individual and remain in position for an extended time
- Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters
- composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an in-dwelling device Treatment may be continued after surgery during the m-body time of the device
- composition could also be used to broaden pe ⁇ operative cover for any surgical technique to prevent bacterial wound infections, especially Staphylococcus aureus wound infections
- compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis
- composition of the invention may be used to bathe an indwelling device immediately before insertion
- the active agent will preferably be present at a concentration of l ⁇ g/ml to lOmg/ml for bathing of wounds or indwelling devices
- a vaccine composition is conveniently in injectable form
- Conventional adjuvants may be employed to enhance the immune response
- a suitable unit dose for vaccination is
- This method describes a rapid way to obtain additional sequence data from partial gene fragments independent of probing a genomic library
- Random sequencing of a 5 aureus genomic library followed by sequence homology searching with the B subtihs P-protein sequence resulted in the identification of a 324 base pair (herein "bp") fragment
- bp 324 base pair
- the first 193 nucleotides of this fragment showed significant homology to the C-terminal half of the B subtihs P-protem and other prokaryotic RNase P proteins
- the N-termmal domain of the putative S aureus RNase P protein was putatively missing
- the reverse strand encoding the C-terminus and upstream the unknown N-termmal sequence of the protein was amplified using primer #1, resulting in single stranded products This amplification of the desired sequence favoured the binding of random primers to that sequence in the next step
- the 5' half of the spp gene was amplified in a two step PCR reaction as described herein
- the PCR products were cleaned using a QIAquick PCR purification column and recovered in 50 ⁇ l water
- the sample was concentrated to a final volume of 25 ⁇ l under vacuum in a SpeedVac® SCI 10 (Savant) 20 ⁇ l were loaded onto a 1 6 mm, 8% polyacrylamide gel containing 7M urea and analyzed by gel electrophoresis
- the gel was stained with efhidium bromide (1 ⁇ g/ml in H2 ⁇ ) to visualize the DNA and photographed The gel was then dried and exposed to film
- Example 3 Shotgun cloning of the PCR fragments: Cloning and sequencing of the PCR fragments The PCR fragments were blunt end cloned into Smal cut pUC19 Ligations of 100 ng vector DNA with 1 0 ⁇ l and 1 5 ⁇ l of PCR products were performed at 16°C overnight E coli XL1 blue cells ( ⁇ -complementing) were transformed by electroporation and plated onto selective plates containing IPTG and x-gal (for blue/white screening) Transformation of these cells resulted in approximately 8 5% white colonies in the presence of PCR products, whereas only 4 6% white colonies could be found in the control ligation without insert White colonies had lost the ability to form the ⁇ -galactosidase holoenzyme as a result of a reading frame disruption in the lacZ' gene and were no longer able to cleave x-gal The reading frame was either disrupted by an insert (in the presence of PCR products) or exonuclease activity of the restriction enzyme
- the 10 plasmids containing an insert were sequenced both w ith the forward and reverse pUC/M 13 sequencing primers 5 of the 6 plasmids that released a fragment after Accl digest harboured an 213bp insert that started with the primer #2 sequence and the known 14bp followed by a sequence of 174 nucleotides that was common to all of the plasmids (Sequence 1. Table 3)
- the insert (Sequence 2. Table 3) was slightly different the first 137 nucleotides were in common with Sequence 1 (dotted line), however the insert sequence extended beyond this and deviated from Sequence 1 (see Table 3)
- GAAAA TTTCA AAGTA CATAA GTCGC ATATA TTGGC CAAAG ATTGT AATAG CAAGA CAGCC AGCTA AAGAT ATGAC GACTT TACAA ATACA GAATA GTCTT GAGCA
- the newly obtained sequence data was drawn together and predicted to represent the complete sequence of the spp structural gene
- the reading frame was determined from a partial sequence of the 3' domain According to this reading frame the start codon ATG could be identified 174bp upstream of primer #2 sequence (see above)
- the nucleotide sequence of the spp gene is shown in Table 1 [SEQ ID NO 2], the start codon (ATG) and stop codon (TAA) are both shown in bold
- the deduced translation product of the spp gene is 1 17 amino acids is also shown in Table 1 [SEQ ID NO 2]
- the translated sequence was aligned with known amino acid sequences of the
- the newly obtained sequence data was used to design PCR primers for the amplification of the full length spp structural gene
- the PCR resulted in a single band of approximately 360bp with a total DNA yield of 2 ⁇ g as determined by spectrophotomet ⁇ cal measurement
- the DNA fragment was cleaned using a QIAquick PCR purification column and recovered in 80 ⁇ l water.
- the pMalc2 vector provides a method for expressing and purifying a protein produced from a cloned gene (New England BioLabs) (see also, Guan, C , Li, P , Riggs, P.D and Inouye, H (1987) Gene 67, 21 -30, Mama, C V et al ( 1988) Gene 74, 365-373 Riggs, P. in Ausubel, F.M. et al. (eds) Current prot. in Molecular Biol. ( 1992): Kellerman and Ferenci ( 1982) Methods in Enzymol. 90, 459-463; Yanisch-Penon, C.
- a cloned gene New England BioLabs
- the cloned gene is inserted downstream from the malE gene of E. coli, which encodes the maltose-binding-protein (MBP), resulting in the expression of an MBP fusion protein.
- the method uses the strong "tac" promotor under the control of the lac repressor and a one step purification of the fusion protein using MBP's affinity for maltose. Unique restriction sites are available between malE and lacZa for inserting the gene of interest, allowing blue/white screening of transformants.
- the vector also contains a recognition site for the specific Factor Xa protease located just 5' to the polylinker. This allows MBP to be cleaved after purification without leaving any vector derived residues attached to the protein of interest when the gene is cloned into the Xmnl site.
- Example 7 Ligation of the spp PCR product into pMalc2 1 ⁇ g of the protein fusion vector pMalc2 was cut with Xmnl and BamHI restriction endonucleases to enable directional cloning of the spp structural gene. To remove the small 15 bp insert the digest was cleaned using QIAquick PCR purification column and the DNA recovered in 90 ⁇ l water. A sample was analysed by agarose gel electrophoresis to ensure complete digestion of the vector. After 30 min of incubation at 37°C with both enzymes the vector was completely cut.
- the spp PCR product was digested with BamHI and cleaned using a QIAquick PCR purification column.
- Vector and insert were ligated overnight in a 20 ⁇ l reaction at 16°C.
- the molar ratio of vector to insert was 1 :5.
- the ligation was desalted using QIAquick Nucleotide Removal columns.
- E. coli XL-1 Blue cells were transformed with 2 ⁇ l desalted ligation reaction. Cells were recovered in 1ml SOC medium after electroporation. 50 ⁇ l of a 1: 100 dilution were plated onto an LB plate containing ampicillin, IPTG and x-gal and incubated at 37°C overnight. 11 white and 1 blue colony were recovered. The 11 white colonies were grown up and the plasmids were isolated from the clones. Sequencing of the plasmids showed that 6 of the 1 1 plasmids contained the correct spp insert. The resulting plasmid was denoted pMalc2::spp, and the fusion protein product MBP-SPP. Example 9 Growth of cells and fusion protein induction in E. coli XL-1 Blue pMalc2::s/ ⁇ ?
- Protein extracts from samples were separated by SDS-PAGE and transferred onto a nitro-cellulose membrane by Western transfer.
- the MBP-SPP fusion protein could be immuno-detected by incubation of the membrane with anti-MBP rabbit serum and HRP- coupled anti-rabbit antibodies followed by ECL detection.
- the Western Blot revealed that 2 proteins were induced upon IPTG addition
- the major protein was of the expected size of approximately 56kD, the second protein, produced in lower amounts, was 10- 15 kD larger.
- Analysis of the spp sequence revealed an accumulation of AUA (lie) and AGA (arg) codons that are rare in E. coli
- the normal frequency of AGA in __. coli is 0.27%, of AUA 0.51 %.
- the spp sequence consists to 4.3% of AGA and 5 1 % of AUA These codons may cause frame shifts and other altered translation events when overexpressing a protein with a high abundance of rare codons.
- E. coli W31 10 pRI952 cells 50 ⁇ l electrocompetent E. coli W31 10 pRI952 cells were transformed with 2 ⁇ l desalted ligation reaction Cells were recovered in 1ml SOC medium after electroporation. lOO ⁇ l of the culture were plated onto selective LB plates (ampillin, cam) containing IPTG and x-gal and incubated at 37°C overnight Too many colonies grew on the plate and could not be counted. 5 white colonies were selected and their plasmids isolated. Sequencing of the plasmids showed that all contained the correct spp insert.
- Example 11 Growth of cells and fusion protein induction in E. coli W3110 pRI952 pMalc2: :spp
- the cells were grown and the expression of the fusion protein was induced as described above The cells kept growing du ⁇ ng the induction period from an A° U 0 of 0 6 to 1 45 Samples were taken from the culture at 0 0, 0 5, 1 5 and 2 5 hours after IPTG addition and protein extracts analysed by SDS-PAGE with Coomassie staining, as well as Western transfer with immunodection Overexpression of the rare tRNAs IleX and ArgU resulted in only one MBP-SPP fusion protein being overexpressed during IPTG induction as detected by the anti-MBP serum Example 12. Purification of the MBP-SPP fusion by affinity chromatography
- the cells E coli W31 10 pRI952 pMalc2 spp
- the cell debris was removed by cent ⁇ fugation and the protein concentration of the crude extract determined using the BIO-RAD Protein Assay The total amount of protein in the crude extract was 86 mg
- a sample of the crude extract was analysed by SDS-PAGE with Coomassie staining which showed that the fusion protein was released from the cells during sonication
- the SP protein readily precipitated upon Factor Xa cleavage and could be separated from MBP by cent ⁇ fugation
- the SPP pellet was washed 3 times and then resuspended in 5ml column buffer
- the MBP remained in solution and was found in the supernatant whereas the pellet consisted mainly of the SP protein and one minor contaminating protein, resulting in a reasonably pure preparation of SPP
- the total SPP yield was 2 18 mg/hter culture
- the SPP preparation was diluted with column buffer to a final concentration of 0 32 mg/ml ImM DTT was added to prevent intermolecular disulfide bond formation between cystein residues
- the addition of 7M urea denatured and apparently completely resolubihzed the protein
- the protein was ahquoted, snap-frozen and stored at -80°C Example 14.
- SP RNA was transcribed m vitro from the plasmid pSPR using T7 RNA polymerase pSPR is a pUC19 derivative that harbours the 5 aureus spi gene behind a T7 promotor
- the plasmid was linearized with BamHI restriction endonuclease to enable run off transcription
- the Ambion MEGAsc ⁇ ptTM T7 kit was used for large scale transcription of the SP RNA
- the transcription reaction was performed at 30 C to allow slow folding of the RNA into the conect conformation during synthesis
- the RNA was cleaned under non- denaturing conditions using CLONTECH Chroma-Spin 30 columns and the RNA recoverd in 40 ⁇ l water
- the quality of the transc ⁇ pt was monitored by gel electrophoresis on a 5% polyacrylamide TBE gel with 7M urea
- the RNA was visualized by UV-shadowmg over a TLC plate
- RNA yield was 140 ⁇ g (determined spectrophotomet ⁇ cally) After cleaning, the RNA was recovered in 40 ⁇ l water resulting in a 29 ⁇ M solution, that was stored at -20°C
- Example 15 In vitro transcription of E. coli ptRNA met incorporating [ ⁇ - ⁇ Zp] UTP E coli ptRNA met , a substrate for RNase P, was transcribed in vitro by T7 RNA polymerase (Epicenter) in the presence of [ ⁇ -32p] UTP to internally label the RNA
- the DNA template pGem3Z-ptRNA was linearized with BstNI restriction endonuclease to allow run-off transcription
- the transcription was performed in a 20 ⁇ l reaction at 37°C for 60m ⁇ n
- To calculate the specific activity of the RNA probe lul samples were removed before and after cleaning, mixed with 5 ml scintillation cocktail and counted in a scintillation counter ptRNA met in p
- RNA molecule p6AT- l was 5' end-labeled with high specific activity [ ⁇ -32p] ATP (6000 ⁇ Ci/ ⁇ l) using bacteriophage T4 polynucleotide kinase.
- the labeling was performed in a 10 ⁇ l reaction at 37°C for 30 min.
- the enzyme was heat-inactivated at 95°C for 2 min.
- p6AT-l was gel purified from a 20% polyacrylamide TBE gel with 7M urea. The RNA was extracted from the gel slice and precipitated with 300mM NaOAc and 2.5 volumes 100% ethanol.
- RNA pellet was washed twice with chilled 70% ethanol. The pellet was air dried and subsequently resuspended in 50 ⁇ l water. 0.5 ⁇ l were spotted onto a filter paper disk and counted in a scintillation counter (Cherenkov analysis).
- E. coli Ml RNA is able to cleave ptRNA racI or the minimal substrate p6AT-l in lOOmM NH4C1, lOOmM TrisCl pH 7.5, lOOmM MgCl 2 .
- the conditions for cleavage of either substrate by S. aureus SP RNA were unknown and clearly deviated from those optimized for E. coli.
- a large number of different buffer conditions were investigated in order to determine optimal buffer conditions for either substrate cleavage by the S. aureus ribozyme.
- Example 19 Effect of the pH on p6AT-l cleavage Buffers containing lOOmM MgC12, 2M KCl and lOOmM TrisCl at a pH of 7.0, 7.5 and 8.0 were tested for the ability to promote p6AT-l cleavage by SP RNA.
- the substrate was cleaved in all three buffers but cleavage was very poor at pH 7.0 and optimal at pH 8.0.
- Example 20 Influence of PEG 8,000 on p6AT-l cleavage
- the addition of polyethylene glycol has been shown to improve substrate cleavage by __. coli Ml RNA.
- the effect of different PEG 8,000 concentrations on p6AT-l cleavage by SP RNA was demonstrated.
- 1%, 2.5% and 5% PEG were added to reactions containing IM KCl, lOOmM TrisCl pH8. lOOmM MgC12.
- Example 21 MgCl2 requirements for p6AT-l processing
- the MgC12 concentration was successively reduced from lOOmM to lOmM to determine the lowest magnesium ion concentration at which the SP RNA could still process the substrate.
- lOOmM, 50mM, 25mM and lOmM MgC12 were tested in a buffer containing 2M KCl, lOOmM TrisCl pH8 and 5% PEG.
- Example 22 Determination of KCl requirements for p6AT-l cleavage The KCl concentration was successively increased from 40mM to 1.5M in lOOmM
- TrisCl pH8, lOOmM MgC12 and 5% PEG TrisCl pH8, lOOmM MgC12 and 5% PEG.
- Example 23 KCl requirements for ptRNA" 111 cleavage by SP RNA ptRNA cl was cleaved under the same buffer conditions as described above.
- ptRNA M was a better substrate than p6AT- l .
- ptRNAmet could be processed at KCl concentrations below 400mM. Some cleavage could already be detected at 20mM KCl, whereas no cleavage of p6AT-l was observed under these conditions. The cleavage rate increased with the KCl concentration. At 150mM KCl more than 50% of the substrate was processed, reaching 82% at 800mM KCl.
- E. coli Ml RNA as a positive control cleaved 80% of the substrate in lOOmM Tris.Cl pH7.5, lOOmM NH4C1, lOOmM MgC12 within 20min.
- the best buffer conditions for ptRNAmet cleavage by SP RNA were IM KCl, lOOmM TrisCl pH8, lOOmM MgC12, 5% PEG.
- Example 24 Determination of the optimal buffer conditions for S. aureus RNase P holoenzyme reactions: p6AT-l cleavage by the holoenzyme
- the S. aureus RNase P holoenzyme cleavage of p6AT-l was investigated over a range of different KCl concentrations at low magnesium ion concentrations. All reactions were performed in lOOmM TrisCl pH8, lOmM MgC12, 5% PEG and 40mM to 1.5M KCl. Cleavage could already be observed at 40mM KCl. The cleavage rate increased with the concentration of monovalent salt, peaking at 150mM, where 50% of the substrate was processed. At higher KCl concentrations the cleavage rate decreased again and p6AT-l processing did not occur at KCl concentrations of 600mM and above. The E.
- coli holoenzyme control cleaved 57% of the p6AT-l within 20min in lOOmM Tris.Cl pH7.5, lOOmM NH4C1, lOmM MgC12.
- the optimal buffer for p6AT-l cleavage by the holoenzyme was 150mM KCl, lOOmM Tris.Cl pH 8.0, lOmM MgCl 2 , 5% PEG 8000.
- p6AT-l was a better substrate for the holoenzyme than for SP RNA, as under optimal conditions only 27% p6AT-l was cleaved as opposed to 50% by the S. aureus RNase P holoenzyme.
- Example 25 MgCl2 requirements for ptRNA cleavage by the holoenzyme
- the 5. aureus RNase P holoenzyme was tested for its ability to cleave ptRNA mcl under different KCl concentrations ranging from 20mM to 1.5M.
- the buffers contained lOOmM Tris Cl pH8, 20mM MgCl 2 , 5% PEG 8000 and xM KCl.
- the holoenzyme was able to cleave ptRNA met at KCl concentrations as low as 20mM.
- the cleavage rate increased with the salt concentration with a peak at 150mM where 55% of the substrate was processed.
- the cleavage rate decreased at KCl concentrations above 200mM but improved again at IM KCl reaching a maximum at 1.5M.
- the cleavage at high salt concentrations was not due to holoenzyme activity but result of SP RNA ribozyme activity at high KCl concentrations.
- ptRNA met was a better substrate for SP RNA than for the S. aureus RNase P holoenzyme.
- the optimal buffer conditions for ptRNAmet cleavage by the holoenzyme were 150mM KCl. lOOmM Tris Cl pH8, 20mM MgCl 2 , 5% PEG.
- Example 27 Strain selection, Library Production and Sequencing
- the polynucleotide having the DNA sequence given in SEQ ID NO: l was obtained from a library of clones of chromosomal DNA of Staphylococcus aureus in E. coli.
- the sequencing data from two or more clones containing overlapping Staphylococcus aureus DNAs was used to construct the contiguous DNA sequence in SEQ ID NO: l .
- Libraries may be prepared by routine methods, for example: Methods 1 and 2 below.
- Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures.
- DNA fragments of up to 1 lkbp in size are rendered blunt by treatment with exonuclease and DNA polymerase. and EcoRI linkers added. Fragments are Hgated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E.coli infected with the packaged library.
- the library is amplified by standard procedures.
- Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for cloning into library vectors (e.g., Rsal, Pall, Alul, Bshl235I), and such fragments are size-fractionated according to standard procedures.
- EcoRI linkers are Hgated to the DNA and the fragments then Hgated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E.coli infected with the packaged library.
- S. aureus RNase P RNA was in vitro transcribed by T7 RNA polymerase and its structure was probed with a variety of enzymatic and chemical probes. Probing data indicates that the 5. aureus RNase P RNA adopts a similar, but unique secondary structure to that of B. subtilis RNase P RNA. Filter binding and gel-shift assays showed that S. aureus RNase P protein binds to the RNA specifically. The binding constant of the complex was measured to be 20 nM.
- (1 ) Frank, D. N. an Pace, N. R. Ann. Review Biochem. (1998), 67, p.153-80.
- a partial homology to the B. subtilis RNase P RNA sequence was identified from a randomly sequenced S. aureus genomic library.
- the complete structural gene encoding the RNase P RNA was amplified and cloned by a 3' primer of known sequence and a 5' degenerate primer designed to form the conserved Pl helix.
- the 5'-end sequence of the RNA was confirmed by primer extension using endogenous S. aureus RNA.
- S. aureus protein gene, spp was identified in a similar manner. The gene was amplified, cloned, and expressed in E. coli as a maltose binding fusion.
- the MBP tag was cleaved off by Factor Xa and the native protein was purified by column chromatography
- the RNA secondary structure and potential tertiary interactions were studied by enzymatic and chemical probing
- the enzymatic probes included RNase Tl, U2, VI , and T2 Chemical probes included DEPC
- the RNase P RNA/protein interactions were in estigated by gel mobility shift and filter binding experiments
- a cloned pre-tRNA pl was used as a substrate for kinetic characterizations for both the holoenzyme and RNA only reactions
- the endogenous RNA used in primer extension experiments was isolated from S aureus cells by TRIZOL method
- Binding isotherm of RNase P RNA obtained by filter binding assay was assessed The 3 '-end labeled RNA was mixed with the protein in the binding buffer containing 20 mM K-Hepes, pH8 0, 0 01 % NP-40, 400 mM NH.OAc, 10 mM MgCl,, and 5% glycererol
- RNaseP protein employs two different modes of RNA interactions, which occupy distinct areas
- the NMR results identify a contiguous interaction site for flexible, single- stranded RNA molecules, representative of the 5'-leader sequence Binding to this site is dominated by electrostatic charge and hydrogen bonding interactions, including main chain hydrogen bonds at the edge of the ⁇ -sheet Cooperative aromatic base stacking interactions play a supportive role
- the argimne-nch motif of RNaseP protein does not bind to single- stranded RNA and is therefore likely to be responsible for the binding to the highly structured P RNA component
- Given the essentiality of RNaseP for the viability of the organism knowledge of the S aureus protein structure and insight into its interaction with RNA will help us to develop RNaseP and RNaseP protein as targets for novel antibiotics against this important pathogen
- DNA or RNA binding proteins are often thermodynamically unstable or even completely unfolded in the absence of their nucleic acid binding partners. This complicates the search for buffer conditions under which the protein is both stable and monodisperse in the concentration range required for NMR spectroscopy (0.5-2 mM).
- Intramolecular NOE upper distance constraints were obtained primarily from two sets of three-dimensional ⁇ N and ⁇ C conelated [1HJH]-NOESY spectra with mixing times of 60 and 150 ms each An additional set of ⁇ C correlated [ 1H, 1H]-NOESY spectra was recorded with the 1 3 C offset centred in the aromatic region of the spectrum
- upper limit constraints derived from the 60 ms and 120 ms were used simultaneously, but a significantly tighter calibration function could be applied to data sets with the shorter mixing time
- Structure calculations were performed using the torsion angle molecular dynamics algorithm implemented m the program DYANA, starting from random conformers (Guntert et al , 1997) Constraints that were considered ambiguous due to chemical shift degeneracy and, simultaneously, spatial proximity of the corresponding atom pairs m preliminary structures were sv stematically analysed with the NOAH option of the DYANA program and discarded whenever several different assignment possibilities were consistent with the calculated structure
- ⁇
- Table 4 and Figure 3a-c) provide an overv iew of the statistical parameters for the final structure calculation A total of 100 conformers were calculated, of which the 20 conformers with the smallest residual violations (l e the lowest DYANA target function) were selected to represent the solution structure of RNaseP protein
- RMSD calculations including side chain non-hydrogen atoms are somewhat biased by the large number of poorly ordered long side chain residues in RNaseP protein, the majority of the polypeptide backbone, including the regular secondary structures, is well defined with an RMSD of 0 62 A for the constrained regions of the peptide
- Consistently lower heteronuclear 1H — X ⁇ N NOE intensities suggest that these peptide segments are relatively mobile and poor structural definition is not due to spectral
- RNaseP protein (Fig 4) has an ot ⁇ -fold, a common architecture in RNA-bind g domains (Varani, 1997)
- the central four-stranded ⁇ -sheet ( ⁇ j residues 23-28, ⁇ 2 31-34, ⁇ 3 82-86, ⁇ 4 44-49) is arranged with a sheet topology of ⁇ i" ⁇ 2" ⁇ 4- ⁇ 3 (from right to left in Fig 4b)
- the ⁇ -sheet is surrounded by three ⁇ -helices ( ⁇ j 12-21 , a?
- Fig. 5 The multiple sequence alignment in Fig. 5 gives an overview of phylogenetically conserved residues, which are most likely to play an important role either in maintaining the structural integrity of the fold or in ligand interactions.
- conserved residues display a characteristic distribution between the hydrophobic core and the protein surface.
- residues indicated by * in Fig. 5 that are buried in the hydrophobic core between the ⁇ -sheet and helices o ⁇ ? and 0:3, only three (Ile62, Ile77 and Vail 05) are conserved throughout the family.
- Interaction region A has a markedly stronger response for AMP compared to 2'-deoxy- AMP and the other Hgands, in particular at residues Ser24 and Val25 on the edge of the ⁇ - sheet, suggesting that the 2'-hydroxyl group and the adenine base interact cooperatively with the protein
- Region B interacts differentially with nucleotides and does not respond to uncharged nucleosides This suggests a role for the two conserved lysine residues in this region, 51 and 52, in very specific electrostatic interactions with the ligand (cmp alignment m Fig 5)
- peptide segments A-D When mapped onto the three-dimensional structure of RNaseP protein, peptide segments A-D form a contiguous surface area (Fig 7) along the direction of the groove formed between helix cq and the ⁇ -sheet and extending to the C-terminal part of helix 03 This area measures approx 18-20 A, which is sufficient to accommodate, in an extended conformation, those 4-6 nucleotides of the leader sequence that are postulated to interact directly with RNaseP protein
- the 6 positive charges in and around the substrate binding site, not counting the RNR-box, provide sufficient countenons for a nucleotide of this size
- the binding surface as outlined by NMR chemical shift data of the polypeptide backbone may slightly overestimate the true extent of the actual RNA-protein contact area, because the minute structural changes causing chemical shift changes may propagate beyond those residues that are in immediate contact with the ligand
- the NMR-denved RNA interaction surface of RNaseP protein is comparable in size to that of other
- arginine- ⁇ ch motif of the RNR-box represents the most likely candidate site for high affinity binding to P RNA, similar to the well established example of the helical arginine- ⁇ ch motif from HIV-1 Rev protein, which interacts with the distorted major groove of double-stranded RNA (Battiste et al , 1996, Peterson and Feigon, 1996 Ye et al , 1996)
- the specificity of an isolated arginine-nch peptide motif for double- stranded RNA is usually low and secondary interactions at other sites of the full length protein are necessary to differentiate between cognate and non-cognate RNA (
- RNaseP protein such sites have not yet been identified and the fact that RNaseP proteins and P RNA from different bacterial species cross-interact to reconstitute active holoenzyme suggests that specificity for the correct binding site may depend on the three-dimensional structure of the P RNA molecule, rather than a particular nucleotide sequence
- the arginine- ⁇ ch motif of the RNR-box is expected to bind preferentially to double-stranded RNA, because binding to a conformationally less restricted single-stranded ligand, such as the 5 '-leader sequence, would incur a heavy entropic penalty in ordering the highly flexible arginine side chains to establish extensive intermolecular hydrogen bonding interactions
- the substrate binding site of RNaseP protein has to carefully balance relatively non-specific long-range electrostatic interactions with more specific and conformationally more demanding short-range interactions, in particular hydrogen bonding, base-stacking with aromatic residues as well as general hydrophobic contacts
- Basic residues in the substrate binding site are generally not highly conserved, suggesting that the overall charge, rather than the precise location of individual charges is important for electrostatic interactions with the phosphate backbone
- the aromatic residues in the binding site, Phel5 and Tyrl9 are highly conserved and likely to engage in aromatic base stacking interactions This is consistent with the experimentally observed preference for pu ⁇ ne over py ⁇ midine bases
- large parts of the interaction surface are devoid of phylogenetically conserved residues, in particular region A This region has a large number of unoccupied main chain hydrogen bonding partners, in particular carbonyl oxygen atoms, at the solvent exposed edge of strand ⁇
- a modified M9 minimal medium with chloride ( lg/1, Cambndge Isotope Laboratories) and either ' • 'C-glucose (2g/l, fermentation grade, Martek) or unlabeled glucose as sole nitrogen and carbons sources were used for the preparation of uniformly ⁇ N ⁇ C-double labeled or ⁇ N single labeled protein
- the protein was expressed as a fusion with maltose binding protein (MBP)
- MBP maltose binding protein
- the fusion protein was solubihzed in 400mM sodium chloride and 1 % CHAPS and purified by cation exchange chromatography on a Biorad Biologic system (20 mM MES buffer pH 6 0, gradient 0- 1M magnesium chloride) The fusion protein was then cleaved with factor Xa at room temperature (Hematologic Technologies Inc ) After cleavage the free C5 protein, which is significantly more basic compared to the MBP-RNaseP protein fusion, is purified to homogeneity in
- the program package DYANA was used to translate NOE peak intensities from the 3D-NOESY spectra into distance constraints Two sets of NOES Y spectra with different mixing times, 60 and 150 ms, were used to denve upper distance constraints, with a looser calibration function for the longer mixing time For mtraresidual and sequential NOEs and for the calculation of local angle constraints with the HABAS routine (Guntert et al , 1991) only 60 ms NOESY spectra were used Hydrogen bond constraints were not introduced throughout the calculation Stereospecific assignments for the diasterotopic methyl groups of vahne and leucine were obtained using biosynthetically directed fractional l 3 C-labehng (Ne ⁇ et al , 1989) ⁇ , ⁇ - Angle constraints for polypeptide backbone were generated from C secondary chemical shifts (Spera & Bax, 1991) A total of 100 DYANA conformers was calculated, using the default simulated annealing macro, and the 20 conformers with the lowest target function values
- sequence alignment was prepared with the program pileup (GCG 9 0, Genetics Computer Group Inc ) using default parameters for gapweight and gaplengthweight)
- GCG 9 Genetics Computer Group Inc
- GeneDoc was used in preparation of Fig 5 (Nicholas and Nicholas, 1997, Version 2 4, www.c ⁇ s com/ ⁇ ketchup/genedoc shtml)
- Residual distance constraint violations 3 sum of violations (A) 24.5 ⁇ 1 6 (20.6 . 27.6) maximum violation (A) 0.55 ⁇ 0.1 (0.4 .. 0 7)
- Residual dihedral angle constraint violations 3 sum (deg.) 28 6 ⁇ 1 1.4 (1 1.4 . . 51.5) maximum violation (deg ) 6.3 ⁇ 2.9 (2.9 . . 16.0)
- a Values are given for the 20 conformers with the lowest DYANA target functions out of a total of 100 conformers calculated.
- the numbers given are mean values ⁇ standard deviations.
- the minimum and maximum values among the 20 conformers are given in parentheses.
- the first number refers to the polypeptide backbone.
- the number in parentheses refers to all non-hydrogen atoms. c
- PROCHECK Laskowski et al., 1996.
- the bacillus subtilis Ochre suppressor sup-3 is located in an operon of seven tRNA genes. 1. Bacteriol. 175, 6512-6517.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00932665A EP1183333A4 (en) | 1999-05-19 | 2000-05-19 | Methods of using rnase p reaction mechanisms of action |
JP2000618431A JP2002544507A (en) | 1999-05-19 | 2000-05-19 | Method using action mechanism of RNaseP reaction |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13480299P | 1999-05-19 | 1999-05-19 | |
US60/134,802 | 1999-05-19 | ||
US14004499P | 1999-06-18 | 1999-06-18 | |
US60/140,044 | 1999-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000070025A1 true WO2000070025A1 (en) | 2000-11-23 |
Family
ID=26832687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/013946 WO2000070025A1 (en) | 1999-05-19 | 2000-05-19 | Methods of using rnase p reaction mechanisms of action |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1183333A4 (en) |
JP (1) | JP2002544507A (en) |
WO (1) | WO2000070025A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
US5744338A (en) * | 1996-01-19 | 1998-04-28 | Smithkline Beecham P.L.C. | DNA encoding seryl tRNA synthetase from Staphylococcus aureus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10113189A (en) * | 1996-06-06 | 1998-05-06 | Smithkline Beecham Corp | New rnasep |
EP1019431A1 (en) * | 1997-09-04 | 2000-07-19 | SmithKline Beecham Corporation | Novel rnase p |
WO2000015775A1 (en) * | 1998-09-17 | 2000-03-23 | Smithkline Beecham Corporation | Rnase p polypeptides |
-
2000
- 2000-05-19 JP JP2000618431A patent/JP2002544507A/en not_active Withdrawn
- 2000-05-19 WO PCT/US2000/013946 patent/WO2000070025A1/en not_active Application Discontinuation
- 2000-05-19 EP EP00932665A patent/EP1183333A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
US5744338A (en) * | 1996-01-19 | 1998-04-28 | Smithkline Beecham P.L.C. | DNA encoding seryl tRNA synthetase from Staphylococcus aureus |
Non-Patent Citations (1)
Title |
---|
See also references of EP1183333A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002544507A (en) | 2002-12-24 |
EP1183333A1 (en) | 2002-03-06 |
EP1183333A4 (en) | 2002-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5932701A (en) | ribA | |
US6346392B1 (en) | Polynucleotides encoding a novel glutamine transport ATP-binding protein | |
EP0904280A1 (en) | STREPTOCOCCUS PNEUMONIAE ASPARTYL tRNA SYNTHETASE | |
US6348342B1 (en) | Compounds | |
EP0811688A2 (en) | Staphylococcus aureus RNase P | |
US6586578B1 (en) | Defl | |
US6010881A (en) | RibG | |
US6649744B1 (en) | Rnase P polypeptides, polynucleotides, and methods using their mechanisms of action | |
WO2000070025A1 (en) | Methods of using rnase p reaction mechanisms of action | |
US6284515B1 (en) | Signal recognition particle polypeptides and polynucleotides | |
US6300119B1 (en) | Stretococcal ERS | |
EP0902087A2 (en) | Histidine kinase | |
EP1114149A1 (en) | Rnase p polypeptides | |
US6444208B1 (en) | Ribonuclease III from Streptococcus pneumoniae | |
US6299883B1 (en) | Tarf | |
US5891678A (en) | DNA encoding the SecA1 polypeptide of Staphylococcus aureus | |
US6350857B1 (en) | Fifty-four homologue (ffh) from streptococcus pneumoniae | |
US20020086024A1 (en) | Novel compounds | |
US20020091236A1 (en) | Novel ribB | |
US6448036B1 (en) | ribB | |
US6348578B1 (en) | Apt | |
CA2233524A1 (en) | Novel compounds | |
US20020086385A1 (en) | Novel era | |
WO1999023212A1 (en) | Novel streptococcal ers | |
EP0913479A2 (en) | Adenine glycosylase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000932665 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10031010 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 618431 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000932665 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000932665 Country of ref document: EP |